Divya Thirumal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Divya Thirumal has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Shuchi Goyal
Chitkara College of Pharmacy, Chitkara University, Punjab, India
5 shared publications - Manjinder Singh
Chitkara College of Pharmacy, Chitkara University, Punjab, India
2 shared publications - Rakesh Kumar Sindhu
School of Pharmacy, Sharda University, Gr Noida
2 shared publications - Thakur Gurjeet Singh
Chitkara College of Pharmacy Chitkara University Rajpura Punjab India
2 shared publications - Varinder Singh
Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, India
2 shared publications - Aayush Sehgal
Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India
1 shared publication
Latest Publications
- 20 May 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (15) , 1331-1346
Mesoporous silica nanoparticles: a versatile carrier platform in lung cancer management
Mesoporous silica nanoparticles (MSNPs) are inorganic nanoparticles that have been comprehensively investigated and are intended to deliver therapeutic agents. MSNPs have revolutionized the therapy for various conditions, especially cancer and infectious diseases. In this article, the viability of MSNPs' administration for lung cancer therapy has been reviewed. However, certain challenges lay ahead in the successful translation such as toxicology, immunology, large-scale production, and regulatory matters have made it extremely difficult to translate such discoveries from the bench to the bedside. This review highlights recent developments, characteristics, mechanism of action and customization for targeted delivery. This review also covers the most recent data that sheds light on MSNPs' extraordinary therapeutic potential in fighting lung cancer as well as future hurdles.
- 20 May 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (15) , 1331-1346
Mesoporous silica nanoparticles: a versatile carrier platform in lung cancer management
Mesoporous silica nanoparticles (MSNPs) are inorganic nanoparticles that have been comprehensively investigated and are intended to deliver therapeutic agents. MSNPs have revolutionized the therapy for various conditions, especially cancer and infectious diseases. In this article, the viability of MSNPs' administration for lung cancer therapy has been reviewed. However, certain challenges lay ahead in the successful translation such as toxicology, immunology, large-scale production, and regulatory matters have made it extremely difficult to translate such discoveries from the bench to the bedside. This review highlights recent developments, characteristics, mechanism of action and customization for targeted delivery. This review also covers the most recent data that sheds light on MSNPs' extraordinary therapeutic potential in fighting lung cancer as well as future hurdles.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S21)
Analogues Rescues Tau Pathologies and Memory Deficits Inhibiting GSK‐3 Signaling using Scaffold morphing and in silico approaches
Background: Alzheimer’s disease (AD is caused by plaque agglomeration and entanglement in several areas of the neural cells, which leads to apoptosis. The main etiology of AD is senile dementia, which is linked to amyloid‐beta (Aβ) deregulation and tau perivascular pathogeny. Hyperphosphorylated tau has propensity for microtubules, which elevates the instability and tau‐protein congregates, leading to accumulation of neurofibrillary tangles (NFTs). Tau hyperphosphorylation is susceptible to GSK‐3 and is an emerging hypothesis for AD. As a result, attempts are made to conduct investigations and further advancements on new analogues capable of inhibiting the GSK‐3 protein, which are currently in the clinical trials.Method: In this analysis, we have evaluated certain GSK‐3 inhibitor variants utilizing scaffolding and framework devise technique with pharmacological characteristics, accompanied by computational screenings (pharmacokinetics and docking).Result: The structure‐based designed analogues interacted effectively with the active amino acids of GSK‐3β target protein. The in silico pharmacokinetic studies revealed their drug‐like properties.Conclusion: The analogues with best interactions and binding scores will be considered in the future to completely demonstrate their potential relevance as viable GSK ‐ 3 inhibitors.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S21)
Open AccessAnalogues Rescues Tau Pathologies and Memory Deficits Inhibiting GSK‐3 Signaling using Scaffold morphing and in silico approaches
Background: Alzheimer’s disease (AD is caused by plaque agglomeration and entanglement in several areas of the neural cells, which leads to apoptosis. The main etiology of AD is senile dementia, which is linked to amyloid‐beta (Aβ) deregulation and tau perivascular pathogeny. Hyperphosphorylated tau has propensity for microtubules, which elevates the instability and tau‐protein congregates, leading to accumulation of neurofibrillary tangles (NFTs). Tau hyperphosphorylation is susceptible to GSK‐3 and is an emerging hypothesis for AD. As a result, attempts are made to conduct investigations and further advancements on new analogues capable of inhibiting the GSK‐3 protein, which are currently in the clinical trials.Method: In this analysis, we have evaluated certain GSK‐3 inhibitor variants utilizing scaffolding and framework devise technique with pharmacological characteristics, accompanied by computational screenings (pharmacokinetics and docking).Result: The structure‐based designed analogues interacted effectively with the active amino acids of GSK‐3β target protein. The in silico pharmacokinetic studies revealed their drug‐like properties.Conclusion: The analogues with best interactions and binding scores will be considered in the future to completely demonstrate their potential relevance as viable GSK ‐ 3 inhibitors.
- 8 December 2023
- Published by Taylor & Francis
- p. 179-204
Smart Targeted Novel Nanocarriers-Based Treatment of Arthritis
An acute or persistent joint infection is known as arthritis, and it may cause a huge variety of symptoms, along with pain, stiffness, a decrease in the variety of motion, and joint abnormalities. The kinds of arthritis, i.e., rheumatoid arthritis (RA) and osteoarthritis had been mentioned in this article. In RA patients, infection was caused by means of pro-inflammatory cytokines like IL-1, IL-6, IL-8, and IL-10. Nonsteroidal anti-inflammatory medications (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and a few biological agents are the most popular RA remedies. However, not one of the remedies available is capable of attaining the final purpose for treating, i.e., drug-free remission. Microemulsions, microspheres, micelles, liposomes, microballoons, co-crystals, nanoemulsions, dendrimers, microsponges, and different strategies had been employed for intrasynovial medicine administration. Because of their size and chemical composition, liposomes have been demonstrated to be specifically effective for maintaining the drugs in the synovial cavity. In contrast to present drugs, novel nanotherapeutic strategies have proven greater selective targeting, extended half-life, subtle bioavailability, and decreased systemic toxicity with the use of nanomaterials and sensible nanomedicines.
- 8 December 2023
- Published by Taylor & Francis
- p. 179-204
Smart Targeted Novel Nanocarriers-Based Treatment of Arthritis
An acute or persistent joint infection is known as arthritis, and it may cause a huge variety of symptoms, along with pain, stiffness, a decrease in the variety of motion, and joint abnormalities. The kinds of arthritis, i.e., rheumatoid arthritis (RA) and osteoarthritis had been mentioned in this article. In RA patients, infection was caused by means of pro-inflammatory cytokines like IL-1, IL-6, IL-8, and IL-10. Nonsteroidal anti-inflammatory medications (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and a few biological agents are the most popular RA remedies. However, not one of the remedies available is capable of attaining the final purpose for treating, i.e., drug-free remission. Microemulsions, microspheres, micelles, liposomes, microballoons, co-crystals, nanoemulsions, dendrimers, microsponges, and different strategies had been employed for intrasynovial medicine administration. Because of their size and chemical composition, liposomes have been demonstrated to be specifically effective for maintaining the drugs in the synovial cavity. In contrast to present drugs, novel nanotherapeutic strategies have proven greater selective targeting, extended half-life, subtle bioavailability, and decreased systemic toxicity with the use of nanomaterials and sensible nanomedicines.
- Open Access
- 13 October 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (10) , 2784
In Silico Approaches to Developing Novel Glycogen Synthase Kinase 3β (GSK-3β)
Alzheimer’s disease (AD) is caused by plaque agglomeration and entanglement in several areas of the neural cells, which leads to apoptosis. The main etiology of AD is senile dementia, which is linked to amyloid-beta (Aβ) deregulation and tau perivascular pathogeny. Hyperphosphorylated tau has a propensity for microtubules, which elevate the instability and tau-protein congregates, leading to accumulation of neurofibrillary tangles (NFTs). Tau hyperphosphorylation is susceptible to GSK-3, which has led to an emerging hypothesis regarding the pathogenesis of AD. Accordingly, attempts have been made to conduct investigations and achieve further advancements on new analogues capable of inhibiting the GSK-3 protein, which are currently in the clinical trials. In this analysis, we have evaluated certain GSK-3 inhibitor variants utilising scaffolding and framework devised techniques with pharmacological characteristics, accompanied by computational screenings (pharmacokinetics and docking). The structure-based designed analogues interacted effectively with the active amino acids of GSK-3β target protein. The in silico pharmacokinetic studies revealed their drug-like properties. The analogues with best interactions and binding scores will be considered in the future to completely demonstrate their potential relevance as viable GSK-3 inhibitors.
- 13 October 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (10) , 2784
Open AccessIn Silico Approaches to Developing Novel Glycogen Synthase Kinase 3β (GSK-3β)
Alzheimer’s disease (AD) is caused by plaque agglomeration and entanglement in several areas of the neural cells, which leads to apoptosis. The main etiology of AD is senile dementia, which is linked to amyloid-beta (Aβ) deregulation and tau perivascular pathogeny. Hyperphosphorylated tau has a propensity for microtubules, which elevate the instability and tau-protein congregates, leading to accumulation of neurofibrillary tangles (NFTs). Tau hyperphosphorylation is susceptible to GSK-3, which has led to an emerging hypothesis regarding the pathogenesis of AD. Accordingly, attempts have been made to conduct investigations and achieve further advancements on new analogues capable of inhibiting the GSK-3 protein, which are currently in the clinical trials. In this analysis, we have evaluated certain GSK-3 inhibitor variants utilising scaffolding and framework devised techniques with pharmacological characteristics, accompanied by computational screenings (pharmacokinetics and docking). The structure-based designed analogues interacted effectively with the active amino acids of GSK-3β target protein. The in silico pharmacokinetic studies revealed their drug-like properties. The analogues with best interactions and binding scores will be considered in the future to completely demonstrate their potential relevance as viable GSK-3 inhibitors.
- Open Access
- 30 May 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (6) , 1589
Pathology and Treatment of Psoriasis Using Nanoformulations
Psoriasis (PSO) is an inflammatory skin condition that causes a variety of diseases and significantly decreases the life characteristics of patients, and substantially diminishes patients’ quality of life. PSO usually impairs the skin and is linked to various disorders. Inflammation pathology does not only damage psoriatic skin; it shows how PSO impinges other body parts. Many variables interact with one another and can impact the etiology of psoriasis directly or indirectly. PSO has an effect on approximately 2% of the world’s population, and significant progress has been made in comprehending and treating the alternative PSO by novel drug delivery systems. Topical, systemic, biological, biomaterials, and phototherapy are some of the useful therapies for PSO. Nonetheless, topical treatments remain the gold standard for treating moderate PSO. The applicability of several nanocarrier systems, such as lipid nanoparticles, metallic nanoparticles, and certain phytocompounds, has been briefly explored. The present review focuses mainly on traditional therapeutic strategies as well as on breakthroughs in nanoformulations and drug delivery methods for several anti-psoriatic drugs.
- 30 May 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (6) , 1589
Open AccessPathology and Treatment of Psoriasis Using Nanoformulations
Psoriasis (PSO) is an inflammatory skin condition that causes a variety of diseases and significantly decreases the life characteristics of patients, and substantially diminishes patients’ quality of life. PSO usually impairs the skin and is linked to various disorders. Inflammation pathology does not only damage psoriatic skin; it shows how PSO impinges other body parts. Many variables interact with one another and can impact the etiology of psoriasis directly or indirectly. PSO has an effect on approximately 2% of the world’s population, and significant progress has been made in comprehending and treating the alternative PSO by novel drug delivery systems. Topical, systemic, biological, biomaterials, and phototherapy are some of the useful therapies for PSO. Nonetheless, topical treatments remain the gold standard for treating moderate PSO. The applicability of several nanocarrier systems, such as lipid nanoparticles, metallic nanoparticles, and certain phytocompounds, has been briefly explored. The present review focuses mainly on traditional therapeutic strategies as well as on breakthroughs in nanoformulations and drug delivery methods for several anti-psoriatic drugs.